Ligand validation:7F9U

HFG: 7-bromo-6-chloro-3-{3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7F9U_HFG_D_901	58%	45%	0.177	0.957	0.36	1.73	-	1	1	0	100%	1
7F9U_HFG_B_901	50%	63%	0.186	0.939	0.46	0.93	-	1	4	0	100%	1
7F9U_HFG_A_901	37%	74%	0.215	0.915	0.28	0.71	-	1	1	0	100%	0.61
7F9U_HFG_C_901	23%	65%	0.247	0.873	0.27	1.06	-	1	1	0	100%	0.61
7F9V_HFG_B_903	89%	76%	0.066	0.944	0.27	0.67	-	1	0	0	100%	1
5XIQ_HFG_B_1002	69%	51%	0.115	0.928	0.96	0.94	-	1	1	0	100%	1
7EVU_HFG_B_901	34%	69%	0.135	0.818	0.28	0.9	-	1	0	0	100%	0.86
8JE6_HFG_A_1802	95%	70%	0.062	0.967	0.35	0.79	-	1	1	0	100%	0.91
5ZNJ_HFG_A_602	90%	5%	0.097	0.979	2.13	3.12	5	8	1	0	100%	1
8JE5_HFG_A_1801	87%	70%	0.078	0.951	0.36	0.78	-	1	1	0	100%	1
8JE7_HFG_A_1801	87%	71%	0.075	0.945	0.33	0.77	-	1	2	0	100%	0.93
7X1O_HFG_A_1901	81%	66%	0.112	0.965	0.28	1.01	-	1	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.